This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China
by Zacks Equity Research
Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.
NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018
by Zacks Equity Research
NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.
Becton, Dickinson (BDX) a Step Closer to Bard Acquisition
by Zacks Equity Research
Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.
Merit Medical Deserves a Place in Your Portfolio: Here's Why
by Zacks Equity Research
A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.
Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak
by Zacks Equity Research
Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
by Zacks Equity Research
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Can CR Bard (BCR) Spring a Surprise This Earnings Season?
by Zacks Equity Research
We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.
Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.
C.R. Bard Shareholders Approve Merger With Becton, Dickinson
by Zacks Equity Research
C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).
Zacks Podcast Highlights: Let's Make a Deal: What's a Merger Arbitrage Strategy?
by Eric Dutram
Merger activity is increasing, and investors need to be prepared. This podcast discusses the 'merger arbitrage' strategy and what you need to know about this approach.
Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?
by Zacks Equity Research
Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition
by Zacks Equity Research
On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).
MedTech Thriving on Consolidation & Expansion: Stocks to Buy
by Zacks Equity Research
The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.
What Drove Becton, Dickinson (BDX) to a New 52-Week High?
by Zacks Equity Research
Share price of Becton, Dickinson and Company (BDX) , based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $196.01 on Jun 27.
C.R. Bard (BCR) Up 1.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
C.R. Bard (BCR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Becton (BDX) Announces $4.5B Follow-On Share Offerings
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.
Stock Market News for April 24, 2017
by Zacks Equity Research
Benchmarks finished in the red on Friday, as investors remained concerned on the outcome of the Presidential election in France
C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.
Bet on These 5 GARP Stocks for Solid Returns
by Zacks Equity Research
The GARP strategy seeks to offer an ideal investment by utilizing the best features of both value and growth investing.
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain
by Zacks Equity Research
We issued an updated research report on C. R. Bard Inc. (BCR) on Mar 8, 2017.
C.R. Bard (BCR) Up 8.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
C.R. Bard (BCR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: C. R. Bard, Illinois Tool Works, Sherwin-Williams, Cintas and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: C. R. Bard, Illinois Tool Works, Sherwin-Williams, Cintas and S&P Global
C. R. Bard (BCR): Moving Average Crossover Alert
by Zacks Equity Research
Are you a technical investor? If so, it may be time to consider C. R. Bard, Inc. (BCR) for your portfolio.
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Medical Product Stocks' Earnings on Jan 26: ABMD, BCR, ABAX
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their quarterly reports on Jan 26.